---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-211873"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:15:22.220400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Magenta Q2 net loss $17.3M; cash $139.4M; MGTA-117 interim data expected Q4 2022

## Summary
- Cash, equivalents, and marketable securities $139.4M as of June 30, 2022; funds operations into Q2 2024.
- Net loss of $17.3M in Q2 2022 vs. $16.9M in Q2 2021; R&D expenses $11.6M, G&A $6.5M.
- MGTA-117 Phase 1/2 trial progressing; interim clinical data from multiple dose cohorts on track for Q4 2022.
- CD45-ADC IND-enabling studies ongoing; in-life toxicology complete; program update expected Q4 2022.
- MGTA-145 stem cell mobilization trial in sickle cell disease initiated; initial data anticipated Q4 2022.

## SEC filing metadata
- accession: 0001193125-22-211873
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522211873/0001193125-22-211873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522211873/d390658d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-211873
- JSON: https://secwatch.observer/filing/0001193125-22-211873.json
- Plain text: https://secwatch.observer/filing/0001193125-22-211873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.